ArticleJournal of cancer research and clinical oncology2013
Biological characteristics of interval cancers: a role for biomarkers in the breast cancer screening.
Article in Journal of cancer research and clinical oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- A comparison of tumour characteristics of screen-detected and interval cancers and their relationship with breast density and AJCC prognostic stage in a UK screening cohort.European radiology · 2026Article
- Risk stratification by ultrasound and mammography for screen-detected non-palpable breast cancer in Chinese women.Frontiers in oncology · 2025Article
- Genetic landscape of interval and screen detected breast cancer.NPJ precision oncology · 2024Article
- Impact of Detection Mode in a Large Cohort of Women Taking Part in a Breast Screening Program.European journal of breast health · 2022Article
- Digital Mammography and Breast Tomosynthesis Performance in Women with a Personal History of Breast Cancer, 2007-2016.Radiology · 2021Observational
- Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis.Breast cancer research and treatment · 2021Article
- Integrating biology and access to care in addressing breast cancer disparities: 25 years' research experience in the Carolina Breast Cancer Study.Current breast cancer reports · 2020Article
- Poor Biological Factors and Prognosis of Interval Breast Cancers: Long-Term Results of Bahçeşehir (Istanbul) Breast Cancer Screening Project in Turkey.JCO global oncology · 2020Article
- Factors Associated with Initial Mode of Breast Cancer Detection among Black Women in the Women's Circle of Health Study.Journal of oncology · 2019Article
- Volumetric breast density and risk of advanced cancers after a negative screening episode: a cohort study.Breast cancer research : BCR · 2018Article
- Cumulative Risk Distribution for Interval Invasive Second Breast Cancers After Negative Surveillance Mammography.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Article
- PAM50 and Risk of Recurrence Scores for Interval Breast Cancers.Cancer prevention research (Philadelphia, Pa.) · 2018Article
- Errors in Mammography Cannot be Solved Through Technology AloneAsian Pacific journal of cancer prevention : APJCP · 2018Review
- MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2017Article
- Imaging Surveillance After Primary Breast Cancer Treatment.AJR. American journal of roentgenology · 2017Review
- The epidemiology, radiology and biological characteristics of interval breast cancers in population mammography screening.NPJ breast cancer · 2017Article
- ADP-ribosylation factor 1 expression regulates epithelial-mesenchymal transition and predicts poor clinical outcome in triple-negative breast cancer.Oncotarget · 2016Article
- Article
- Tumor phenotype and breast density in distinct categories of interval cancer: results of population-based mammography screening in Spain.Breast cancer research : BCR · 2014Article
- Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients.Breast cancer research and treatment · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn a population-based screening program, a percentage of tumors remain undetected; these tumors comprise a heterogeneous group, and they are more likely to have adverse prognostic features. The aim of this study was to identify differences in biological characteristics of screen-detected versus interval breast cancers in a population-based screening program according to molecular subtypes. MATERIALS AND
methodsWe analyzed the population-based data from a long-running screening program in the area of Florence. Data on screening history and on age, T and N status, grade, histotype, hormonal status and Ki-67 and HER2 expression were retrieved. Subtypes of breast cancer were defined on the expression of ER, PR, Ki-67 and HER2: luminal A if ER/PR+, HER2- and Ki67 <14 %, luminal B (HER2 negative) if ER/PR+, HER2- and Ki67 ≥14 %, luminal B (HER2 positive) if ER/PR+ and HER2+, triple negative if ER/PR-and HER2-, HER2 positive if ER/PR- and HER2+. Association between molecular subtypes and mode of detection will be evaluated by a logistic regression model adjusted for the potential confounding variables.
resultsInformation about biomarkers was known for 277 cases, 211 screening-detected and 66 interval cancers. Among interval cases, the triple-negative cancers were more represented than luminal A (OR = 3.52; CI, 1.112-11.13; p = 0.0319), while the proportion of HER2+ was quite similar (OR = 1.57; p = 0.4709).
conclusionAlthough made on a small number of cases, our results suggest a difference in distribution of molecular subtypes according to mode detection, confirming the results of earlier studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.